TapewireFind a company

person · Reporting owner

Elazzouzi Amy

Disclosed activity across 1 company

Tapewire entity
18047
SEC CIK
0002042910

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Aura Biosciences, Inc.AURA · Entity 5142SVP, Finance & PAOSeptember 01, 2026September 01, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aura Biosciences, Inc.

Report date September 01, 2026 · Filed September 01, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect143,600 Reported balance After 2026-09-01 transaction · row 1
1 source row

Row 1 · 2026-09-01 · Grant · Acquired 23,540 · Balance 143,600

F1: The reported transaction represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock upon vesting and settlement. These RSUs shall vest in four substantially equal annual installments, subject to the Reporting Person's continued service to the Issuer on each vesting date, with the first tranche vesting on September 15, 2027.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.43 · Expires 2036-09-01Direct46,460 Reported balance After 2026-09-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-09-01 · Grant · Acquired 46,460 · Balance 46,460

F2: The stock option shall vest as to 1/48th of the total award monthly, subject to the reporting person's continued service to the Issuer on each vesting date, with the first tranche vesting on October 1, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: The reported transaction represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock upon vesting and settlement. These RSUs shall vest in four substantially equal annual installments, subject to the Reporting Person's continued service to the Issuer on each vesting date, with the first tranche vesting on September 15, 2027.

F2: The stock option shall vest as to 1/48th of the total award monthly, subject to the reporting person's continued service to the Issuer on each vesting date, with the first tranche vesting on October 1, 2026.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 01, 2026 Filed Sep 1, 2026 21:23 UTC Aura Biosciences, Inc. AURA · Entity 5142 GrantStock Option (Right to Buy) · Derivative 46,460 $0.00 Strike: $7.43 $0.00
Disclosure

SEC source: 0002042910-26-000003 · form4-09012026_090904.xml · derivative · entry 2

Elazzouzi Amy · CIK 0002042910 · SVP, Finance & PAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,460

Underlying: Common Stock · 46,460 shares

Expires 2036-09-01

F2 · derivative.exercise_date: The stock option shall vest as to 1/48th of the total award monthly, subject to the reporting person's continued service to the Issuer on each vesting date, with the first tranche vesting on October 1, 2026.

Read SEC document
September 01, 2026 Filed Sep 1, 2026 21:23 UTC Aura Biosciences, Inc. AURA · Entity 5142 GrantCommon Stock 23,540 $0.00 $0.00
Disclosure

SEC source: 0002042910-26-000003 · form4-09012026_090904.xml · nonDerivative · entry 1

Elazzouzi Amy · CIK 0002042910 · SVP, Finance & PAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 143,600

F1 · shares: The reported transaction represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock upon vesting and settlement. These RSUs shall vest in four substantially equal annual installments, subject to the Reporting Person's continued service to the Issuer on each vesting date, with the first tranche vesting on September 15, 2027.

Read SEC document
March 02, 2026 Filed Mar 3, 2026 21:05 UTC Aura Biosciences, Inc. AURA · Entity 5142 GrantStock Option (Right to Buy) · Derivative 80,472 $0.00 Strike: $6.14 $0.00
Disclosure

SEC source: 0001193125-26-088150 · ownership.xml · derivative · entry 2

Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,472

Underlying: Common Stock · 80,472 shares

Expires 2036-03-02

F2 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.

Read SEC document
March 02, 2026 Filed Mar 3, 2026 21:05 UTC Aura Biosciences, Inc. AURA · Entity 5142 GrantCommon Stock 44,528 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-088150 · ownership.xml · nonDerivative · entry 1

Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,060

F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on January 15, 2027, subject to the Reporting Person's continued service as of each such vesting date.

Read SEC document
February 17, 2026 Filed Feb 18, 2026 00:47 UTC Aura Biosciences, Inc. AURA · Entity 5142 SaleCommon Stock 8,549 $5.06 $43,257.94
Disclosure

SEC source: 0001193125-26-055494 · ownership.xml · nonDerivative · entry 1

Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,532

F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.04 to $5.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 20, 2026 Filed Jan 20, 2026 23:41 UTC Aura Biosciences, Inc. AURA · Entity 5142 SaleCommon Stock 1,581 $4.86 $7,683.66
Disclosure

SEC source: 0001193125-26-016939 · ownership.xml · nonDerivative · entry 1

Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,081

F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

Read SEC document
October 29, 2025 Filed Oct 29, 2025 21:05 UTC Aura Biosciences, Inc. AURA · Entity 5142 SaleCommon Stock 896 $6.35 $5,689.60
Disclosure

SEC source: 0001193125-25-256620 · ownership.xml · nonDerivative · entry 1

Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,662

F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

Read SEC document
August 18, 2025 Filed Aug 18, 2025 20:34 UTC Aura Biosciences, Inc. AURA · Entity 5142 Exercise / conversionStock Option (Right to Buy) · Derivative 2,319 $0.00 Strike: $4.25 $0.00
Disclosure

SEC source: 0000950170-25-109767 · ownership.xml · derivative · entry 15

Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,319 shares

Expires 2030-03-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option is fully vested.

Read SEC document
August 18, 2025 Filed Aug 18, 2025 20:34 UTC Aura Biosciences, Inc. AURA · Entity 5142 Exercise / conversionStock Option (Right to Buy) · Derivative 1,094 $0.00 Strike: $3.16 $0.00
Disclosure

SEC source: 0000950170-25-109767 · ownership.xml · derivative · entry 14

Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,094 shares

Expires 2029-02-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option is fully vested.

Read SEC document
August 18, 2025 Filed Aug 18, 2025 20:34 UTC Aura Biosciences, Inc. AURA · Entity 5142 Exercise / conversionStock Option (Right to Buy) · Derivative 4,744 $0.00 Strike: $2.74 $0.00
Disclosure

SEC source: 0000950170-25-109767 · ownership.xml · derivative · entry 13

Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,744 shares

Expires 2028-02-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option is fully vested.

Read SEC document
August 18, 2025 Filed Aug 18, 2025 20:34 UTC Aura Biosciences, Inc. AURA · Entity 5142 Exercise / conversionStock Option (Right to Buy) · Derivative 547 $0.00 Strike: $5.21 $0.00
Disclosure

SEC source: 0000950170-25-109767 · ownership.xml · derivative · entry 12

Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 547 shares

Expires 2027-04-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option is fully vested.

Read SEC document
August 18, 2025 Filed Aug 18, 2025 20:34 UTC Aura Biosciences, Inc. AURA · Entity 5142 Exercise / conversionStock Option (Right to Buy) · Derivative 547 $0.00 Strike: $5.48 $0.00
Disclosure

SEC source: 0000950170-25-109767 · ownership.xml · derivative · entry 11

Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 547 shares

Expires 2026-10-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option is fully vested.

Read SEC document
August 18, 2025 Filed Aug 18, 2025 20:34 UTC Aura Biosciences, Inc. AURA · Entity 5142 Exercise / conversionStock Option (Right to Buy) · Derivative 1,094 $0.00 Strike: $5.48 $0.00
Disclosure

SEC source: 0000950170-25-109767 · ownership.xml · derivative · entry 10

Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,094 shares

Expires 2026-04-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option is fully vested.

Read SEC document
August 18, 2025 Filed Aug 18, 2025 20:34 UTC Aura Biosciences, Inc. AURA · Entity 5142 Exercise / conversionStock Option (Right to Buy) · Derivative 2,554 $0.00 Strike: $5.07 $0.00
Disclosure

SEC source: 0000950170-25-109767 · ownership.xml · derivative · entry 9

Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,554 shares

Expires 2025-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option is fully vested.

Read SEC document
August 18, 2025 Filed Aug 18, 2025 20:34 UTC Aura Biosciences, Inc. AURA · Entity 5142 SaleCommon Stock 7,722 $6.70 $51,737.40
Disclosure

SEC source: 0000950170-25-109767 · ownership.xml · nonDerivative · entry 8

Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,558

F1 · kind: On August 18, 2025, the Reporting Person exercised long held stock options to purchase 12,899 shares of the Issuer's common stock, 7,722 of which were sold to cover the exercise price of such options.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.57 to $6.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 18, 2025 Filed Aug 18, 2025 20:34 UTC Aura Biosciences, Inc. AURA · Entity 5142 Exercise / conversionCommon Stock 2,319 $4.25 $9,855.75
Disclosure

SEC source: 0000950170-25-109767 · ownership.xml · nonDerivative · entry 7

Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,280

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On August 18, 2025, the Reporting Person exercised long held stock options to purchase 12,899 shares of the Issuer's common stock, 7,722 of which were sold to cover the exercise price of such options.

Read SEC document
August 18, 2025 Filed Aug 18, 2025 20:34 UTC Aura Biosciences, Inc. AURA · Entity 5142 Exercise / conversionCommon Stock 1,094 $3.16 $3,457.04
Disclosure

SEC source: 0000950170-25-109767 · ownership.xml · nonDerivative · entry 6

Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 91,961

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On August 18, 2025, the Reporting Person exercised long held stock options to purchase 12,899 shares of the Issuer's common stock, 7,722 of which were sold to cover the exercise price of such options.

Read SEC document
August 18, 2025 Filed Aug 18, 2025 20:34 UTC Aura Biosciences, Inc. AURA · Entity 5142 Exercise / conversionCommon Stock 4,744 $2.74 $12,998.56
Disclosure

SEC source: 0000950170-25-109767 · ownership.xml · nonDerivative · entry 5

Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,867

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On August 18, 2025, the Reporting Person exercised long held stock options to purchase 12,899 shares of the Issuer's common stock, 7,722 of which were sold to cover the exercise price of such options.

Read SEC document
August 18, 2025 Filed Aug 18, 2025 20:34 UTC Aura Biosciences, Inc. AURA · Entity 5142 Exercise / conversionCommon Stock 547 $5.21 $2,849.87
Disclosure

SEC source: 0000950170-25-109767 · ownership.xml · nonDerivative · entry 4

Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,123

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On August 18, 2025, the Reporting Person exercised long held stock options to purchase 12,899 shares of the Issuer's common stock, 7,722 of which were sold to cover the exercise price of such options.

Read SEC document
August 18, 2025 Filed Aug 18, 2025 20:34 UTC Aura Biosciences, Inc. AURA · Entity 5142 Exercise / conversionCommon Stock 547 $5.48 $2,997.56
Disclosure

SEC source: 0000950170-25-109767 · ownership.xml · nonDerivative · entry 3

Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,576

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On August 18, 2025, the Reporting Person exercised long held stock options to purchase 12,899 shares of the Issuer's common stock, 7,722 of which were sold to cover the exercise price of such options.

Read SEC document
August 18, 2025 Filed Aug 18, 2025 20:34 UTC Aura Biosciences, Inc. AURA · Entity 5142 Exercise / conversionCommon Stock 1,094 $5.48 $5,995.12
Disclosure

SEC source: 0000950170-25-109767 · ownership.xml · nonDerivative · entry 2

Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,029

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On August 18, 2025, the Reporting Person exercised long held stock options to purchase 12,899 shares of the Issuer's common stock, 7,722 of which were sold to cover the exercise price of such options.

Read SEC document
August 18, 2025 Filed Aug 18, 2025 20:34 UTC Aura Biosciences, Inc. AURA · Entity 5142 Exercise / conversionCommon Stock 2,554 $5.07 $12,948.78
Disclosure

SEC source: 0000950170-25-109767 · ownership.xml · nonDerivative · entry 1

Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,935

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On August 18, 2025, the Reporting Person exercised long held stock options to purchase 12,899 shares of the Issuer's common stock, 7,722 of which were sold to cover the exercise price of such options.

Read SEC document
April 16, 2025 Filed Apr 17, 2025 00:36 UTC Aura Biosciences, Inc. AURA · Entity 5142 SaleCommon Stock 897 $5.49 $4,924.53
Disclosure

SEC source: 0000950170-25-054954 · ownership.xml · nonDerivative · entry 1

Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,381

F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.49 to $5.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
February 18, 2025 Filed Feb 19, 2025 00:31 UTC Aura Biosciences, Inc. AURA · Entity 5142 SaleCommon Stock 1,404 $7.75 $10,881.00
Disclosure

SEC source: 0000950170-25-022654 · ownership.xml · nonDerivative · entry 1

Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,278

F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

Read SEC document
February 03, 2025 Filed Feb 4, 2025 22:51 UTC Aura Biosciences, Inc. AURA · Entity 5142 GrantStock Option (Right to Buy) · Derivative 29,760 $0.00 Strike: $7.68 $0.00
Disclosure

SEC source: 0000950170-25-013825 · ownership.xml · derivative · entry 2

Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,760

Underlying: Common Stock · 29,760 shares

Expires 2035-02-02

F2 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vest on February 3, 2026 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.

Read SEC document
February 03, 2025 Filed Feb 4, 2025 22:51 UTC Aura Biosciences, Inc. AURA · Entity 5142 GrantCommon Stock 45,240 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-013825 · ownership.xml · nonDerivative · entry 1

Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,682

F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on February 15, 2026, subject to the Reporting Person's continued service as of each such vesting date.

Read SEC document
January 21, 2025 Filed Jan 22, 2025 02:09 UTC Aura Biosciences, Inc. AURA · Entity 5142 SaleCommon Stock 1,001 $7.67 $7,679.17
Disclosure

SEC source: 0000950170-25-007494 · ownership.xml · nonDerivative · entry 1

Elazzouzi Amy · CIK 0002042910 · Vice President, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,442

F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.67 to $7.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
October 29, 2024 Filed Oct 30, 2024 00:23 UTC Aura Biosciences, Inc. AURA · Entity 5142 SaleCommon Stock 553 $10.74 $5,938.39
Disclosure

SEC source: 0000950170-24-118475 · ownership.xml · nonDerivative · entry 1

Elazzouzi Amy · CIK 0002042910 · Vice President, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,443

F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.65 to $10.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.